{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:30:56Z","timestamp":1790217056970,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82441017"],"award-info":[{"award-number":["82441017"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes","award":["JYY2023-3 to Z. Li"],"award-info":[{"award-number":["JYY2023-3 to Z. Li"]}]},{"name":"Peking University-Golden Resource \u201cTengyun Clinical Research Program\u201d"},{"name":"Science Foundation of Peking University Cancer Hospital","award":["2022-1"],"award-info":[{"award-number":["2022-1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1245\/s10434-025-17397-4","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T09:43:49Z","timestamp":1748943829000},"page":"6817-6828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Utilizing Combined Circulating Tumor DNA and Tumor Markers to Evaluate Neoadjuvant Therapy Response and Predict Recurrence in Patients with Locally Advanced Gastric Cancer"],"prefix":"10.1245","volume":"32","author":[{"given":"Honglin","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongning","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"issue":"3","key":"17397_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"17397_CR2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(5):584\u201390.","journal-title":"Chin Med J"},{"key":"17397_CR3","doi-asserted-by":"crossref","first-page":"17036","DOI":"10.1038\/nrdp.2017.36","volume":"3","author":"J Ajani","year":"2017","unstructured":"Ajani J, Lee J, Sano T, Janjigian Y, Fan D, Song S. Gastric adenocarcinoma. Nature Rev Disease Primers. 2017;3:17036.","journal-title":"Nature Rev Disease Primers"},{"issue":"12","key":"17397_CR4","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamasurg.2019.3473","volume":"154","author":"Z Li","year":"2019","unstructured":"Li Z, Shan F, Ying X, Zhang Y, Jian-Yu E, Wang Y, Ren H, Su X, Ji J. Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a randomized clinical trial. JAMA Surg. 2019;154(12):1093\u2013101.","journal-title":"JAMA Surg"},{"issue":"1","key":"17397_CR5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11\u201320.","journal-title":"N Engl J Med"},{"issue":"13","key":"17397_CR6","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","volume":"29","author":"M Ychou","year":"2011","unstructured":"Ychou M, Boige V, Pignon J, Conroy T, Bouch\u00e9 O, Lebreton G, Ducourtieux M, Bedenne L, Fabre J, Saint-Aubert B, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715\u201321.","journal-title":"J Clin Oncol"},{"issue":"10184","key":"17397_CR7","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"S Al-Batran","year":"2019","unstructured":"Al-Batran S, Homann N, Pauligk C, Goetze T, Meiler J, Kasper S, Kopp H, Mayer F, Haag G, Luley K, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357.","journal-title":"Lancet"},{"issue":"26","key":"17397_CR8","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"Y Kang","year":"2021","unstructured":"Kang Y, Yook J, Park Y, Lee J, Kim Y, Kim J, Ryu M, Rha S, Chung I, Kim I, et al. PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant s-1 for resectable advanced gastric cancer. J Clinical Oncol. 2021;39(26):2903\u201313.","journal-title":"J Clinical Oncol"},{"issue":"8","key":"17397_CR9","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, Yu J, Bu Z, Chen L, Du Y, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncology. 2021;22(8):1081\u201392.","journal-title":"Lancet Oncology"},{"issue":"11","key":"17397_CR10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/jjco\/29.11.550","volume":"29","author":"T Yamao","year":"1999","unstructured":"Yamao T, Kai S, Kazami A, Koizumi K, Handa T, Takemoto N, Maruyama M. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. Jpn J Clin Oncol. 1999;29(11):550\u20135.","journal-title":"Jpn J Clin Oncol"},{"key":"17397_CR11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1186\/1477-7819-12-397","volume":"12","author":"Z Sun","year":"2014","unstructured":"Sun Z, Zhang N. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World J Surg Oncol. 2014;12:397.","journal-title":"World J Surg Oncol"},{"issue":"2","key":"17397_CR12","first-page":"176","volume":"71","author":"ML Cheng","year":"2021","unstructured":"Cheng ML, Pectasides E, Hanna GJ, Parsons HA, Choudhury AD, Oxnard GR. Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions. CA Cancer J Clin. 2021;71(2):176\u201390.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"17397_CR13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1158\/1078-0432.CCR-20-2299","volume":"27","author":"J Zhou","year":"2021","unstructured":"Zhou J, Wang C, Lin G, Xiao Y, Jia W, Xiao G, Liu Q, Wu B, Wu A, Qiu H, et al. Serial circulating tumor DNA in predicting and monitoring the effect of neoadjuvant chemoradiotherapy in patients with rectal cancer: a prospective multicenter study. Clin Cancer Res. 2021;27(1):301\u201310.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"17397_CR14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","volume":"32","author":"MJM Magbanua","year":"2021","unstructured":"Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, Tin A, Salari R, Shchegrova S, Pawar H, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32(2):229\u201339.","journal-title":"Ann Oncol"},{"issue":"8","key":"17397_CR15","first-page":"e254","volume":"10","author":"C Zhang","year":"2020","unstructured":"Zhang C, Chen Z, Chong X, Chen Y, Wang Z, Yu R, Sun T, Chen X, Shao Y, Zhang X, et al. Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies. Cancer Sci. 2020;10(8):e254.","journal-title":"Cancer Sci"},{"issue":"10","key":"17397_CR16","doi-asserted-by":"crossref","first-page":"e1003771","DOI":"10.1371\/journal.pmed.1003771","volume":"18","author":"C Abbosh","year":"2021","unstructured":"Abbosh C, Swanton C. ctDNA: an emerging neoadjuvant biomarker in resectable solid tumors. PLoS Med. 2021;18(10):e1003771.","journal-title":"PLoS Med"},{"issue":"9","key":"17397_CR17","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, Bariani GM, De Jesus Acosta A, Doi T, Longo F, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33(9):929\u201338.","journal-title":"Ann Oncol"},{"issue":"2","key":"17397_CR18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.22.00686","volume":"41","author":"T Andre","year":"2023","unstructured":"Andre T, Tougeron D, Piessen G, de la Fouchardiere C, Louvet C, Adenis A, Jary M, Tournigand C, Aparicio T, Desrame J, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol. 2023;41(2):255\u201365.","journal-title":"J Clin Oncol"},{"issue":"5","key":"17397_CR19","first-page":"2579","volume":"11","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Wang L, Ni S, Tan C, Cai X, Huang D, Sheng W. Clinicopathological features and prognostic value of mismatch repair protein deficiency in gastric cancer. Int J Clin Exp Pathol. 2018;11(5):2579\u201387.","journal-title":"Int J Clin Exp Pathol"},{"issue":"6","key":"17397_CR20","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/cam4.1502","volume":"7","author":"L Wang","year":"2018","unstructured":"Wang L, Zhang Q, Ni S, Tan C, Cai X, Huang D, Sheng W. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status. Cancer Med. 2018;7(6):2612\u201320.","journal-title":"Cancer Med"},{"issue":"5","key":"17397_CR21","first-page":"440","volume":"24","author":"Y Liu","year":"2021","unstructured":"Liu Y, Zang FL, Qiu ZQ, Guo YH, Luo Y, Sun L, Zhao S, Shao B, Liang H, Sun Y. Association of status of mismatch repair protein expression and EB virus infection with clinicopathological parameters in 886 gastric adenocarcinoma patients. Zhonghua Wei Chang Wai Ke Za Zhi. 2021;24(5):440\u20138.","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"issue":"15","key":"17397_CR22","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"A Bolger","year":"2014","unstructured":"Bolger A, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114\u201320.","journal-title":"Bioinformatics"},{"issue":"14","key":"17397_CR23","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with burrows-wheeler transform. Bioinformatics. 2009;25(14):1754\u201360.","journal-title":"Bioinformatics"},{"issue":"14","key":"17397_CR24","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","volume":"28","author":"CT Saunders","year":"2012","unstructured":"Saunders CT, Wong WSW, Swamy S, Becq J, Murray LJ, Cheetham RK. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics. 2012;28(14):1811\u20137.","journal-title":"Bioinformatics"},{"key":"17397_CR25","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1186\/1471-2164-15-732","volume":"15","author":"KC Amarasinghe","year":"2014","unstructured":"Amarasinghe KC, Li J, Hunter SM, Ryland GL, Cowin PA, Campbell IG, Halgamuge SK. Inferring copy number and genotype in tumour exome data. BMC Genomics. 2014;15:732.","journal-title":"BMC Genomics"},{"issue":"4","key":"17397_CR26","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.","journal-title":"Genome Biol"},{"issue":"1","key":"17397_CR27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, Flicek P, Cunningham F. The ensembl variant effect predictor. Genome Biol. 2016;17(1):122\u201335.","journal-title":"Genome Biol"},{"issue":"6","key":"17397_CR28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine. 2017;23(6):703\u201313.","journal-title":"Nature Medicine"},{"issue":"1","key":"17397_CR29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.","journal-title":"Genome Med"},{"issue":"6","key":"17397_CR30","first-page":"1342","volume":"24","author":"Z Li","year":"2021","unstructured":"Li Z, Jia Y, Zhu H, Xing X, Pang F, Shan F, Li S, Wang D, Zhao F, Ma T, et al. Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy. Gastric Cancer Official J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2021;24(6):1342\u201354.","journal-title":"Gastric Cancer Official J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"issue":"6","key":"17397_CR31","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s10120-018-0830-1","volume":"21","author":"Z Li","year":"2018","unstructured":"Li Z, Wang Y, Shan F, Ying X, Wu Z, Xue K, Miao R, Zhang Y, Ji J. ypTNM staging after neoadjuvant chemotherapy in the Chinese gastric cancer population: an evaluation on the prognostic value of the AJCC eighth edition cancer staging system. Gastric Cancer. 2018;21(6):977\u201387.","journal-title":"Gastric Cancer"},{"issue":"9","key":"17397_CR32","doi-asserted-by":"crossref","first-page":"eaay4211","DOI":"10.1126\/sciadv.aay4211","volume":"6","author":"Z Li","year":"2020","unstructured":"Li Z, Gao X, Peng X, Chen M-JM, Li Z, Wei B, et al. Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy. Sci Adv. 2020;6(9):eaay4211.","journal-title":"Sci Adv"},{"issue":"12","key":"17397_CR33","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1245\/s10434-007-9574-6","volume":"14","author":"JC Mansour","year":"2007","unstructured":"Mansour JC, Tang L, Shah M, Bentrem D, Klimstra DS, Gonen M, Kelsen DP, Brennan MF, Coit DG. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol. 2007;14(12):3412\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"17397_CR34","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/cas.13314","volume":"108","author":"J Gao","year":"2017","unstructured":"Gao J, Wang H, Zang W, Li B, Rao G, Li L, Yu Y, Li Z, Dong B, Lu Z, et al. Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer. Cancer Sci. 2017;108(9):1881\u20137.","journal-title":"Cancer Sci"},{"issue":"15","key":"17397_CR35","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","volume":"25","author":"N Leighl","year":"2019","unstructured":"Leighl N, Page R, Raymond V, Daniel D, Divers S, Reckamp K, Villalona-Calero M, Dix D, Odegaard J, Lanman R, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25(15):4691\u2013700.","journal-title":"Clin Cancer Res"},{"key":"17397_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00299","volume":"3","author":"M Pritchett","year":"2019","unstructured":"Pritchett M, Camidge D, Patel M, Khatri J, Boniol S, Friedman E, Khomani A, Dalia S, Baker-Neblett K, Plagnol V, et al. Prospective clinical validation of the in vision first-lung circulating tumor DNA assay for molecular profiling of patients with advanced nonsquamous non-small-cell lung cancer. JCO Precis Oncol. 2019;3:1.","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"17397_CR37","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1093\/annonc\/mdy417","volume":"29","author":"S Kruger","year":"2018","unstructured":"Kruger S, Heinemann V, Ross C, Diehl F, Nagel D, Ormanns S, Liebmann S, Prinz-Bravin I, Westphalen C, Haas M, et al. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Ann Oncol. 2018;29(12):2348\u201355.","journal-title":"Ann Oncol"},{"issue":"18","key":"17397_CR38","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1158\/1078-0432.CCR-16-3155","volume":"23","author":"F Garlan","year":"2017","unstructured":"Garlan F, Laurent-Puig P, Sefrioui D, Siauve N, Didelot A, Sarafan-Vasseur N, Michel P, Perkins G, Mulot C, Blons H, et al. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study). Clin Cancer Res. 2017;23(18):5416\u201325.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"17397_CR39","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/annonc\/mdv177","volume":"26","author":"J Tie","year":"2015","unstructured":"Tie J, Kinde I, Wang Y, Wong H, Roebert J, Christie M, Tacey M, Wong R, Singh M, Karapetis C, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 2015;26(8):1715\u201322.","journal-title":"Ann Oncol"},{"issue":"8","key":"17397_CR40","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","volume":"24","author":"S Goldberg","year":"2018","unstructured":"Goldberg S, Narayan A, Kole A, Decker R, Teysir J, Carriero N, Lee A, Nemati R, Nath S, Mane S, et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin Cancer Res. 2018;24(8):1872\u201380.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"17397_CR41","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1245\/s10434-023-13194-z","volume":"30","author":"Y Morimoto","year":"2023","unstructured":"Morimoto Y, Matsuda S, Kawakubo H, Nakamura K, Kobayashi R, Hisaoka K, Okui J, Takeuchi M, Aimono E, Fukuda K, et al. Tumor burden monitoring with circulating tumor DNA during treatment in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2023;30(6):3747\u201356.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"17397_CR42","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10120-021-01258-6","volume":"25","author":"AE Slagter","year":"2021","unstructured":"Slagter AE, Vollebergh MA, Caspers IA, van Sandick JW, Sikorska K, Lind P, Nordsmark M, Putter H, Braak JPBM, Meershoek-Klein Kranenbarg E, et al. Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial. Gastric Cancer. 2021;25(2):401\u201310.","journal-title":"Gastric Cancer"},{"issue":"3","key":"17397_CR43","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1078-0432.CCR-21-2404","volume":"28","author":"T Henriksen","year":"2022","unstructured":"Henriksen T, Tarazona N, Frydendahl A, Reinert T, Gimeno-Valiente F, Carbonell-Asins J, Sharma S, Renner D, Hafez D, Roda D, et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin Cancer Res. 2022;28(3):507\u201317.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"17397_CR44","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","volume":"5","author":"J Tie","year":"2019","unstructured":"Tie J, Cohen J, Wang Y, Christie M, Simons K, Lee M, Wong R, Kosmider S, Ananda S, McKendrick J, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 2019;5(12):1710\u20137.","journal-title":"JAMA Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17397-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17397-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17397-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:01:39Z","timestamp":1754150499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17397-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["17397"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17397-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest for this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This study was reviewed and approved by the Ethical Board at Peking University Cancer Hospital and Institute, with ethics approval document no. 2022KT62. Clinical samples were obtained with written informed consent from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}